Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib for Visual Processing in Parkinson's Disease Psychosis
NCT03661125Phase 1Unknown
- Sponsor
- King's College London
- Start
- Apr 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of saracatinib in Parkinson's disease (PD) (2 arms), sponsored by King's College London. Primary endpoint: Difference between study drug and placebo in BOLD activity in the ventral visual stream during visual recognition vs. the control task measure using fMRI at 2 months. Status: unknown.
02
Drugs
saracatinib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03661125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03661125.